SKL-11197

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameSKL-11197

Drug Alias NameSKL-11197SKL-NP

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of Action12-lipoxygenase inhibitorsHyperpolarization-activated cyclic nucleotide-gated channel modulatorsArachidonate 15-lipoxygenase inhibitors +[4]

TargetsArachidonate 15-lipoxygenaseVoltage-gated calcium channelHyperpolarization-activated cyclic nucleotide-gated channel +[4]

Therapy Area/IndicationsDiabetic Neuropathies

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSK Biopharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSk Life Science Inc

Active IndicationsN/A

Inactive IndicationsDiabetic Neuropathies

Other Information

ATC CodeN/A